Hello, everyone, and welcome to Allurion fourth quarter earnings call. Please note that this call is being recorded. After the speaker's prepared remarks, there will be a question and answer session.

Second, the rapid weight loss achieved through the Allurion Balloon, the lifestyle modification strategies offered through the Allurion program and the remote monitoring through the Allurion ...

Reports Q4 revenue $5.6M, compared to $8.2M for the same period in 2023. The year-over-year decrease in revenue was primarily due to the ...

Shares of Allurion Technologies, Inc. (ALUR) tumbled nearly 11% on Wednesday morning after the company’s fourth-quarter (Q4) ...

Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient ...

The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including ...

Looking ahead, Allurion Technologies expects steady revenue growth throughout 2025, with projected revenues of approximately $30 million. The company is focusing on launching innovative products, ...

including a next-generation balloon with enhanced features, and is preparing for a potential U.S. market entry pending FDA approval. Allurion also anticipates reaching EBITDA positive status by 2026.